

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YSB Inc.

藥師幫股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9885)

VOLUNTARY ANNOUNCEMENT PURCHASE OF SHARES FOR SHARE INCENTIVE PLAN

This announcement is made by YSB Inc. (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis.

Reference is made to the 2023 share incentive plan adopted by the Company on 12 June 2023 (the “**Share Incentive Plan**”), a summary of the principal terms of which is set out in the section headed “Share Incentive Plans – 2023 Share Incentive Plan” in Appendix IV to the Company’s prospectus dated 15 June 2023 (the “**Prospectus**”). Terms used herein shall have the same meanings as defined in the Prospectus unless otherwise stated.

The Board is pleased to announce that during the period between 23 March 2026 (being the last day of the blackout period, on which the Company published its 2025 annual results announcement) and 21 July 2026 (being the first day of the blackout period for publishing the 2026 interim results announcement of the Company) (both dates exclusive), pursuant to the trust arrangement as entered into between the Company and the trust institution (the “**Trustee**”), the Trustee purchased on-market a total of 35,365,600 Shares for the purpose of satisfying awards granted under the Share Incentive Plan (the “**Awards**”) at a total consideration of HK\$158,756,310 with an average price of approximately HK\$4.49 per Share. Pursuant to the trust arrangement, the Trustee shall hold on trust and manage the funds and properties for the benefit of the eligible participants in accordance with the Share Incentive Plan and the trust arrangement (the “**Trust Fund**”).

The Awards include, but not limited to, the share options granted by the Company under the Share Incentive Plan to Mr. Buzhen Zhang (“**Mr. Zhang**”) and Mr. Fei Chen (“**Mr. Chen**”) (details of which are set out in the Company’s announcement dated 24 March 2026). Upon the exercise of such share options, the Shares repurchased will be transferred from the Trust Fund to eligible participants, therefore no new Shares will be allotted and issued by the Company, and there will not be any dilution of the issued share capital of the Company.

In addition, the Company may grant further awards under the Share Incentive Plan in the future, and such awards may also be satisfied by the Trustee out of the purchased Shares pursuant to the trust arrangement. The Company may instruct the Trustee to make further purchases of additional Shares, and further announcements for such purchases will be made from time to time on a voluntary basis.

The Board is of the view that the current share price of the Company is below its intrinsic value and may not adequately reflect the Company's business prospects; and accordingly, this provides a good opportunity for the Trustee to purchase the Shares on-market to replenish the Trust Fund. In addition, the purchase of Shares in accordance with the Share Incentive Plan demonstrates the Company's confidence in its business outlook and prospects, and also serves as part of our strategy to attract talents and align the interests of key employees with the interests of the Company for the sustainable growth of the Group in the long term. As the largest digital pharmaceutical platform serving businesses outside of hospitals in China, we will continue to promote the healthy development of the industry in line with the rapid development of the internet healthcare industry through our highly efficient internet pharmaceutical distribution network and innovative healthcare technology, so as to better fulfil our mission of "To make quality medical care and good medicine accessible to all (讓好醫好藥普惠可及)".

By order of the Board
YSB Inc.
Mr. Buzhen Zhang
Chairman and executive Director

Hong Kong, 20 August 2026

As of the date of this announcement, the Board comprises Mr. Buzhen Zhang and Mr. Fei Chen as executive Directors, and Mr. Ziyang Zhu as the non-executive Director, and Ms. Rong Shao, Mr. Sam Hanhui Sun and Mr. Hongqiang Zhao as independent non-executive Directors.